Abstract
The chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor that has been reported to modulate inflammatory responses in various rodent models of asthma, allergic rhinitis and atopic dermatitis. In this study, we describe the biological and pharmacological properties of {(7R)-7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetic acid (MK-7246), a novel synthetic CRTH2 antagonist. We show that MK-7246 1) has high affinity for the human, monkey, dog, rat, and mouse CRTH2, 2) interacts with CRTH2 in a reversible manner, 3) exhibits high selectivity over all prostanoid receptors as well as 157 other receptors and enzymes, 4) acts as a full antagonist on recombinant and endogenously expressed CRTH2, 5) demonstrates good oral bioavailability and metabolic stability in various animal species, 6) yields ex vivo blockade of CRTH2 on eosinophils in monkeys and sheep, and 7) significantly blocks antigen-induced late-phase bronchoconstriction and airway hyper-responsiveness in sheep. MK-7246 represents a potent and selective tool to further investigate the in vivo function of CRTH2.
Footnotes
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.068585.
-
ABBREVIATIONS:
- PGD2
- prostaglandin D2
- CRTH2
- chemoattractant receptor-homologous molecule expressed on T-helper cells
- Th2
- T-helper cells type 2
- DK-PGD2
- 13,14-dihydro-15-keto-prostaglandin D2
- MK-7246
- {(7R)-7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetic acid
- DP
- prostaglandin D2 receptor
- TP
- thromboxane A2
- HEK
- human embryonic kidney
- PBS
- phosphate-buffered saline
- PK
- pharmacokinetic
- PD
- pharmacodynamic
- AZ11805131
- 2-[2-(4-ethylsulfonyl-2-methylphenyl)-4-(trifluoromethyl)phenoxy]acetic acid
- AZ11665362
- [2,5-dimethyl-3-(8-methylquinolin-4-yl)-1H-indole-1-yl]acetic acid
- AM156
- (2′-((cyclopropanecarbonylethylamino)methyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl)acetic acid
- AM206
- (5-(2-((benzoyloxycarbonylethylamino)methyl)-4-trifluoromethylphenyl)pyridin-3-yl)acetic acid
- L-002245377
- (2S,3S,4S,5R,6S)-6-[({(7R)-7-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl}acetyl)oxy]-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
- Amira's compound 23
- {8-[[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9-tetrahydro-5H-pyrido[3,2-]indol-5-yl} acetic acid
- TM30089
- {(3)-3-[[(4-fluorophenyl)sulfonyl](methyl)amino]-1,2,3,4-tetrahydro-9H-carbazol-9-yl} acetic acid.
- Received September 2, 2010.
- Accepted October 5, 2010.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
